Years of collaboration across disciplines sparked an idea: let’s work together to bring streamlined custom solutions to our rare disease clients.
This idea, shared by Chris Smith, Jean Campbell, Patti Engel, Doug Paul and David Lapidus was the impetus for the Rare Collective, a trusted team of rare disease experts spanning several key disciplines:
- Patient Advocacy – Jean Campbell, JF Campbell Consultants
- Market Development, Research and Strategy – Patti Engel, Engage Health
- Data Analytics and Modeling – David Lapidus, LapidusData
- Pricing, Reimbursement Modeling – Doug Paul, MME
- Communications and Public Relations – Chris Smith, SmithSolve
The team’s mission is simple – partner with companies to help guide the efficient development, commercialization and adoption of innovative therapies and devices to rare disease communities by partnering. Orphan drug development continues to evolve as industry seeks to develop new treatments, underscoring the need for companies to raise awareness, involve patient organizations and anticipate issues throughout the drug development cycle.
Chris proudly brings more than 25 years of experience in healthcare communications to the collective. An expert in rare disease communication, Chris knows the intricacies in addressing the scientific, medical, clinical, social and economic aspects of orphan drug development.
Chris is motivated to connect people with valuable information and insight that can improve patient outcomes and advance organizations.
“Having worked with the members of the Rare Collective throughout the years, we’ve learned just how effective and natural it is to collaborate to help clients navigate the different facets of orphan drug development,” said Chris.
To learn more about how The Rare Collective can help define your rare disease narrative, please visit rarecollective.org.